10-Q: CeriBell Q3 Loss Widens Amid Strong Revenue Growth, Legal Battle

CeriBell, Inc. reported a significant increase in net loss for Q3 2025 and the nine months ended September 30, 2025, despite robust growth in both product and subscription revenues, while also initiating patent infringement litigation.

Summary

• Net loss for the three months ended September 30, 2025, increased to $13.5 million from $10.4 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $39.9 million from $27.9 million in the prior year period.
• Total revenue for Q3 2025 grew 31% to $22.6 million, driven by a 28% increase in product revenue to $17.0 million and a 44% increase in subscription revenue to $5.6 million.
• Total revenue for the nine months ended September 30, 2025, increased 37% to $64.3 million, with product revenue up 35% to $48.6 million and subscription revenue up 43% to $15.7 million.
• Gross profit for Q3 2025 rose 33% to $19.9 million, achieving an 88% gross margin, up from 87% in Q3 2024.
• Operating expenses surged by 39% in Q3 2025 to $34.6 million and by 49% for the nine months to $100.4 million, primarily due to increased headcount in R&D, sales and marketing, and general and administrative functions.
• The company had $168.5 million in cash and cash equivalents and marketable securities as of September 30, 2025, and believes this is sufficient to fund operations for at least the next 12 months.
• CeriBell filed patent infringement complaints against Natus Medical Incorporated and its subsidiaries on July 7, 2025, alleging infringement on six patents related to its EEG headband and electrode design.
• The U.S. International Trade Commission (USITC) initiated an investigation into these patent infringement claims on August 6, 2025.

Sentiment

Score: 4

Explanation: While revenue growth is strong and gross margins are healthy, the significant increase in net losses and operating expenses, coupled with ongoing litigation and a reliance on future capital, indicates a challenging path to profitability and warrants a cautious sentiment. The company is in a high-growth, high-investment phase, but the widening losses are a concern.

Positives

• Total revenue increased significantly by 31% for the three months and 37% for the nine months ended September 30, 2025, demonstrating strong market adoption.
• Product revenue grew 28% in Q3 2025 and 35% for the nine months, driven by new customers and increased headband utilization.
• Subscription revenue saw substantial growth of 44% in Q3 2025 and 43% for the nine months, indicating successful adoption of Clarity subscriptions.
• Gross profit increased by 33% in Q3 2025 and 40% for the nine months, with overall gross margin improving to 88% from 87% in the prior year quarter.
• Product gross margin improved by 2% to 86% in Q3 2025, partially due to decreased cost of goods sold per unit as non-variable costs were allocated among a larger number of units.
• The company maintains a strong liquidity position with $168.5 million in cash and cash equivalents and marketable securities, expected to fund operations for at least the next 12 months.
• Received Breakthrough Device Designation from the FDA in September 2022 for delirium detection and monitoring, potentially expediting development and review.
• Extended exclusivity of licensed patents from Stanford University to May 2036, strengthening intellectual property position.

Negatives

• Net loss widened by 29% to $13.5 million for the three months ended September 30, 2025, compared to $10.4 million in the prior year.
• Accumulated deficit increased to $206.8 million as of September 30, 2025, from $166.9 million at December 31, 2024.
• Operating expenses increased substantially by 39% in Q3 2025 and 49% for the nine months, outpacing revenue growth and contributing to increased losses.
• Sales and marketing expenses surged by 48% in Q3 2025 and 60% for the nine months, primarily due to increased headcount for commercial expansion.
• Research and development expenses increased by 47% in Q3 2025 and 46% for the nine months, driven by higher personnel and clinical study costs.
• General and administrative expenses rose 22% in Q3 2025 and 35% for the nine months, due to increased headcount and public company-related legal and professional fees, including intellectual property enforcement activities.
• Cash and cash equivalents decreased significantly from $194.4 million at the beginning of the nine-month period to $23.7 million at September 30, 2025, primarily due to purchases of marketable securities.
• Net cash used in operating activities increased to $30.0 million for the nine months ended September 30, 2025, from $25.1 million in the prior year period.

Risks

• Limited operating history and significant business changes make it difficult to evaluate future prospects and manage growth effectively.
• Continued net losses are expected in the foreseeable future, and profitability cannot be assured or sustained.
• Dependence on sales from the Ceribell System means failure to achieve substantial market acceptance or diminished confidence in products would be harmful.
• Highly competitive industry with larger, more established competitors (e.g., Natus, Nihon Kohden) that may offer similar or superior products at more attractive prices.
• Challenges in adapting manufacturing and production capacities to evolving demand patterns, potentially leading to excess inventory or inability to meet increased demand.
• Exposure to foreign operational and trade risks due to reliance on contract manufacturers in China and Vietnam, including tariffs, supply chain disruptions, and political instability.
• Inability to innovate at the pace of competitors, particularly in AI, could negatively affect operating results and future prospects.
• Future international sales will subject the company to additional costs and risks, including varying regulatory requirements and market practices.
• Failure to attract and retain senior management and other key personnel, especially in a competitive market, could materially adversely affect the business.
• Products are complex and can contain defects, leading to product liability lawsuits, reputational harm, or costly investigations.
• The estimated addressable market for products may be smaller than anticipated, impacting growth potential.
• Alternative technologies or therapies for neurological conditions could decrease demand for Ceribell products.
• Rapid growth could strain personnel resources and infrastructure, leading to inefficiencies and unanticipated costs.
• Macroeconomic conditions (inflation, high interest rates, geopolitical instability) could adversely impact demand, increase costs, and affect hospital spending.
• Shutdowns of the U.S. federal government could delay regulatory reviews, litigation proceedings, or government program implementations.
• Inadequate reimbursement for diagnostic tests using Ceribell products could diminish sales or affect profitability.
• Relationships with contracted physicians for remote EEG interpretation services must comply with state laws prohibiting corporate practice of medicine or fee splitting, and non-compliance could lead to penalties.
• Extensive government regulation and oversight in the U.S. (e.g., FDA) means failure to comply could harm the business.
• Ongoing regulatory review and scrutiny, with failure to comply with post-marketing requirements potentially leading to enforcement actions or product recalls.
• Products must be manufactured in accordance with applicable laws and regulations (e.g., QSR), and non-compliance could force recalls or production termination.
• Products may cause or contribute to adverse medical events, requiring FDA reporting, and discovery of serious safety issues or recalls could negatively impact the company.
• Misuse or off-label use of products could result in injuries, product liability suits, reputational harm, or regulatory sanctions.
• Legislative or regulatory reforms in the U.S. (e.g., Quality Management System Regulation) may increase manufacturing, marketing, or distribution costs.
• Risks related to obtaining necessary foreign regulatory clearance or approvals for international expansion.
• Failure to comply with the Foreign Corrupt Practices Act (FCPA), economic and trade sanctions regulations, and similar laws could subject the company to penalties.
• Dependence on single-source suppliers for critical components makes the company vulnerable to supply shortages and price fluctuations.
• Reliance on third parties for preclinical studies and clinical trials means they may not properly carry out duties or meet deadlines.
• Actual or perceived failures to comply with data privacy and security laws (HIPAA, CCPA, GDPR) could adversely affect the business.
• Risks associated with the use and development of AI and machine learning models, including incorrect design, biased data, or evolving regulatory frameworks.
• Information technology system failures, cyber attacks, or cybersecurity deficiencies could lead to business disruption, data loss, or legal liabilities.
• Inability to obtain, maintain, enforce, and protect intellectual property rights (patents, trademarks, trade secrets) could harm competitive position.
• Patent prosecution is expensive, time-consuming, and complex, with no assurance that applications will result in issued patents or provide sufficient protection.
• Changes in U.S. or foreign patent laws or their interpretations could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world due to varying laws and enforcement standards.
• Potential for claims challenging inventorship or ownership of patents and other intellectual property rights.
• Dependence on licensed intellectual property rights (e.g., from Stanford University) means termination or disputes could harm the business.
• Failure to protect confidential information and trade secrets could harm the value of products and competitive position.
• Inadequate protection of trademarks and trade names could impede brand recognition.
• Use of third-party open source software components carries risks of non-compliance with licenses, potentially restricting product sales or affecting proprietary information.
• Manufacturing restrictions related to licensed intellectual property rights developed with U.S. government grants (Bayh-Dole Act) could limit manufacturing locations or lead to compulsory licensing.
• Ability to use net operating loss carryforwards (NOLs) may be limited due to Internal Revenue Code Sections 382 and 383 or state tax law.
• Effective tax rate may vary significantly due to changes in tax laws, regulations, or other factors.
• Venture loan and security agreement contains restrictions that limit operational flexibility and could lead to default if covenants are breached.
• Cash deposits with financial institutions exceed insured limits, posing a risk in case of bank failure.
• Increased costs and additional regulations as a public company could lower profits or make business operations more difficult.
• Inability to design, implement, and maintain effective internal control over financial reporting could lead to loss of investor confidence.
• No intention to pay dividends in the foreseeable future, meaning return on investment depends on stock price appreciation.
• Market price of common stock may be volatile due to various factors, including financial performance fluctuations and industry trends.
• Future securities issuances could result in significant dilution to stockholders and impair the market price of common stock.
• Potential need for additional capital to support business growth, which may not be available on favorable terms or at all, and could dilute existing stockholders.
• Principal stockholders and management own a significant percentage of stock, enabling them to exert significant control over stockholder-approved matters.
• Provisions in charter documents and Delaware law could discourage takeovers and entrench management.
• Claims for indemnification by directors, officers, and employees may reduce available funds.
• Exclusive forum provision in charter documents could limit stockholders' ability to obtain a favorable judicial forum.
• Insurance may not cover all potential losses or liabilities, leading to substantial out-of-pocket payments.

Future Outlook

The company expects to incur losses in the near term as it continues to focus on developing and promoting new and existing products and expanding its corporate infrastructure, including costs associated with being a public company. It plans to expand its direct sales organization in the United States, pursue additional regulatory clearances in Europe and other international markets, and engage in market access initiatives. Research and development expenses are expected to increase to improve algorithms, expand indications, and develop products beyond acute care. Sales and marketing expenses are also projected to rise for market penetration and international expansion. General and administrative expenses will increase to support business growth and public company operations. The company believes existing cash and marketable securities are sufficient to fund planned operating expenses and capital expenditures for at least the next 12 months, but acknowledges the need for additional capital if cash generation is lower or expenses are higher than expected.

Management Comments

• We expect to incur losses in the near term as we continue to focus on the development and promotion of new and existing products and expand our corporate infrastructure, including the costs associated with being a public company.
• Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these financial statements.
• We may experience lower than expected cash generated from operating activities or greater than expected capital expenditures, cost of revenue, or operating expenses, and may need to raise additional capital to fund operations, further research and development activities, or acquire, invest in, or license other businesses, assets, or technologies.
• We intend to expand the size of our direct sales organization in the United States to support our efforts to drive further adoption and utilization of the Ceribell System.
• While our current commercial focus is on the United States, we have received a CE Mark for the Ceribell System in Europe, and we intend to pursue additional regulatory clearances in Europe and elsewhere outside of the United States. We also plan to engage in market access initiatives in attractive international regions in which we see significant opportunity.
• We invest in research and development efforts with the goal of driving continuous improvements in our current system and solutions and expanding the clinical application of our system and AI algorithms, in the acute care setting and beyond.

Industry Context

The company operates in the competitive medical device industry, specifically targeting the acute care setting for neurological conditions with its point-of-care EEG platform. The industry is characterized by rapid technological innovation, dependence on third-party payers, and stringent government regulations. The company's focus on AI-powered algorithms aligns with broader industry trends towards integrating artificial intelligence into medical diagnostics for improved efficiency and accuracy. However, it faces competition from established conventional EEG providers like Natus and Nihon Kohden, as well as other companies developing rapid EEG systems. Macroeconomic conditions, including inflation and supply chain pressures, are impacting operating costs across the industry, and regulatory changes, such as the FDA's Quality Management System Regulation, require continuous adaptation.

Comparison to Industry Standards

• The company's Ceribell System aims to address unmet needs in acute care settings, where conventional EEG systems, primarily offered by competitors like Natus Medical Incorporated and Nihon Kohden, have technological and operational limitations leading to diagnostic delays.
• The company's AI-powered Clarity algorithm is a key differentiator, though the filing notes that an earlier version was found to be unable to detect seizure or status epilepticus in certain ICU patients who had cardiac arrest, highlighting the ongoing challenge of AI accuracy and validation compared to human expert interpretation.
• The company's gross margin of 88% for the nine months ended September 30, 2025, is strong, indicating efficient cost management relative to revenue generation, especially for a medical technology company with both product and subscription offerings.
• The significant increase in operating expenses, particularly in sales and marketing (60% increase for 9M 2025), reflects an aggressive growth strategy common in the medical device industry for market penetration, but also contributes to widening net losses, which may be higher than some more mature, profitable industry peers.
• The company's reliance on contract manufacturers in China and Vietnam for key sub-assemblies is a common industry practice for cost efficiency but exposes it to geopolitical and supply chain risks, similar to many global medical device manufacturers.

Management Changes

Corporate Governance

Legal Proceedings

• On July 7, 2025, CeriBell, Inc. filed patent infringement complaints against Natus Medical Incorporated and related subsidiaries with the U.S. International Trade Commission (USITC) and the U.S. District Court for the District of Delaware.
• The complaints allege that Natus is infringing on six patents related to the Ceribell EEG headband and electrode design and engaging in unfair competition.
• CeriBell requested the USITC to investigate these claims and issue an exclusion order to bar the importation of infringing Natus products into the United States.
• CeriBell also requested an award of damages in the District Court for the alleged infringement, as well as other costs and expenses.
• On August 6, 2025, the USITC instituted an investigation of these claims pursuant to Section 337 of the Tariff Act of 1930.
• A federal government shutdown may cause delays in the progress of the USITC investigation and related proceedings.

Related Party Transactions

• The company paid Dr. Josef Parvizi, a Director and Co-Founder, $49,000 for consulting services and related expense reimbursement for the three months ended September 30, 2025, and $146,000 for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Experience dilution from stock option exercises and potential future capital raises, and face increased net losses, but benefit from strong revenue growth and intellectual property enforcement efforts. The stock price may be volatile due to litigation and financial performance.
• Employees: Benefit from the Employee Stock Purchase Plan (ESPP) and 401(k) matching contributions, enhancing compensation and retention. Increased headcount across R&D, sales, and G&A indicates job growth.
• Customers (Hospitals): Benefit from increased awareness and adoption of the Ceribell System, potentially leading to improved patient outcomes. However, they face potential challenges with reimbursement policies and the need for continuous education on the system's benefits.
• Suppliers: The company's reliance on third-party manufacturers in China and Vietnam creates interdependence, with risks related to supply chain disruptions and trade policies.
• Competitors (e.g., Natus Medical Incorporated): Directly impacted by patent infringement litigation initiated by CeriBell, potentially facing exclusion orders and damages.

Next Steps

• Expand the direct sales organization in the United States to drive further adoption and utilization of the Ceribell System.
• Pursue additional regulatory clearances in Europe and other international markets for the Ceribell System.
• Engage in market access initiatives in attractive international regions.
• Continue research and development initiatives to introduce enhancements, features, and improvements to the Ceribell System and Clarity algorithm.
• Expand the Ceribell System into new indications beyond seizures, with technical validation already begun for several additional indications.
• Monitor and manage the patent infringement complaints against Natus Medical Incorporated, including the USITC investigation.
• Evaluate the impact of FASB ASU No. 2024-03 on disclosures for fiscal years beginning after December 15, 2026.
• Comply with the FDA's Quality Management System Regulation (QSR) final rule, effective February 2, 2026.

Key Dates

Recommendation

CeriBell demonstrates strong revenue growth and improving gross margins, indicating increasing market adoption of its innovative EEG system. However, this growth comes at a significant cost, with widening net losses driven by substantial increases in operating expenses across R&D, sales, and G&A. The company's liquidity position is currently adequate for the next 12 months, but future capital raises are explicitly mentioned as a possibility. The ongoing patent infringement litigation against a major competitor introduces both potential upside (if successful) and significant legal costs and management distraction. Given the high-growth, high-investment phase, coupled with increasing losses and legal uncertainties, a 'hold' recommendation is appropriate. Investors should monitor the trajectory of operating expenses relative to revenue, the progress of the litigation, and any future capital raise announcements before making further investment decisions.

Keywords

Medical Technology, EEG, Neurological Conditions, Seizure Detection, AI-powered Algorithm, Clarity, Acute Care, Medical Device, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Operating Expenses, Intellectual Property, Patent Infringement, Natus Medical, Regulatory Compliance, Liquidity, Risk Factors, Stock-based Compensation, Capital Resources, Public Company Costs, Supply Chain, International Markets, Cybersecurity, Corporate Governance